Plain-English translation of NCT07050394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called , which uses a type of genetic material (self-replicating RNA) packaged in tiny fat particles to help treat colorectal cancer. The medication is given as an injection into the vein. Researchers want to see whether this treatment is safe and whether it can slow or shrink tumors in people whose cancer has advanced and cannot be removed with surgery.
Standard colorectal cancer treatments do not work for all patients—some people's cancers continue to grow despite chemotherapy or targeted drugs, or they cannot tolerate these standard treatments. This trial exists to explore whether this new RNA-based approach might offer hope to patients who have exhausted traditional options.
You likely qualify if…
You likely don't qualify if…
You would receive three initial injections of the medication: one at the start, one two weeks later, and one four weeks after that. Then you would receive ongoing injections every three weeks for as long as the treatment is working and you are tolerating it well. Your doctor will monitor your health with blood tests and imaging scans to check how your cancer is responding and watch for any side effects. After receiving at least two doses, you may be offered the option to combine this medication with other cancer treatments, depending on your doctor's assessment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China